Table 1.

Schizophrenia and BPD.

	Study Design	Country	No.	Age Group	Disease	Daily Dosage (g/d)	Duration	Rating Scale	Outcome
Amminger et al., 2010 [50]	Randomised, double-blind, placebo controlled trial	Austria	81	13–25 years	- Individuals at ultra-high risk of psychotic disorder.	1.2g/d n-3 PUFAs or placebo	12 weeks	- PANSS - MADRS - GAF - SCID-I/P	The cumulative conversion rates to psychotic disorder were 4.9% (2 of 41) in the n-3 group and 27.5% (11 of 40) in the placebo group.
Amminger et al., 2015 [53]	Post hoc subgroup analysis	Austria	81	13–25 years	- Individuals at ultra-high risk of psychotic disorder. - BPD	1.2g/d n-3 PUFAs or placebo	12 weeks	- PANSS - MADRS - GAF	N-3 PUFAs provided improvements in functioning and symptoms.
Mcgorry et al., 2017	Randomised, double-blind, placebo controlled trial	Australia	304	13–40 years	- Individuals at ultra-high risk of psychotic disorder.	1.4 g/d n-3 PUFAs together with CBCM or placebo with CBCM or placebo	24 weeks	- YMRS - BPRS - CDRS	No significant difference between ω-3 PUFAs and placebo in transition rate.
Pawełczyk et al., 2016 [51]	Randomised, double-blind, placebo controlled trial	Poland	71	16–35 years	-Individuals at first-episode schizophrenia	2.2 g/d n-3 PUFAs or placebo	26 weeks	- PANSS - CDSS - GAF - CGI-S	50% improvement in total PANSS score was achieved significantly more frequently in the n-3 PUFAS group than in the placebo group.

BPD: Borderline Personality Disorder; BPRS: Brief Psychosis Rating Scale; CDRS: Children’s Depression Rating Scale; CDSS: Calgary Depression Scale for Schizophrenia; CGI-S Clinical Global Impressions scale; GAF: Global Assessment of functioning MADRS: Montgomery-Åsberg Depression Rating Scale; PANSS: Positive and Negative Syndrome Scale; SCID-I/P: The Structured Clinical Interview for DSM-IV Axis I Disorders; YMRS: Young Mania Rating Scale.